John Freshley is head of business development for Asalyxa Bio. John is an entrepreneur, company builder and leader having founded, launched and/or led 8 early stage biotech companies, including drug development companies in oncology and ophthalmology.

He recently led ONL Therapeutics as its CEO from discovery through pre-clinical development, with lead product entering Phase 1 in Q4 2019.

He previously launched Compendia Bioscience as start-up CEO and remained as Chief Business Officer through its acquisition by Life Technologies (now Thermo Fisher).